slides · global inventory
11 Golden Circle
Loop collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 13,983
Current window 10,471-10,500
Pages 467
Rows per page 30
Loop
10,471-10,500 of 13,983
17
The slide highlights specific clinical trial names and their associated indications, with a focus on the camizestrant program.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · VisualizationLoop · Golden Circle1 hit
18
AstraZeneca | Results Presentation Deck | 42 slidesAstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · VisualizationLoop · Golden Circle1 hit
19
Slide 19 of a presentation; includes revenue charts for CVRM and R&I segments and a list of key Q4 2024 dynamics.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · VisualizationLoop · Golden Circle1 hit
20
The slide uses a structured table format to map specific drug brands to their growth drivers and strategic expansion plans.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · VisualizationLoop · Golden Circle1 hit
21
The slide content is obscured by a large grey box, leaving only the title visible.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · VisualizationLoop · Golden Circle1 hit
22
AstraZeneca | Results Presentation Deck | 42 slidesAstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · VisualizationLoop · Golden Circle1 hit
23
The chart shows a stacked bar breakdown of revenue by product (Ultomiris, Soliris, Strensiq, Koselugo PS, Koselugo CR, Other) across 8 quarters.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · VisualizationLoop · Golden Circle1 hit
24
The slide uses a structured list format to detail growth strategies for three specific pharmaceutical products.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · VisualizationLoop · Golden Circle1 hit
25
The slide highlights a pipeline of NMEs (New Molecular Entities) with specific focus on complement biology.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · VisualizationLoop · Golden Circle1 hit
09
The slide uses a chronological progression framework to illustrate the evolution of digital business models.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations Beat · SatisfactionLoop · Golden Circle1 hit
10
Uses a 'passenger travel' analogy to explain the freight booking market structure.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations Beat · SatisfactionLoop · Golden Circle1 hit
24
The chart displays LS Mean Change from baseline across multiple dose groups (25, 50, 100, 200 ug) versus placebo.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
25
The slide outlines a clinical trial protocol with a primary endpoint at week 6 and a 40-week extension phase.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
26
Includes study timeline, randomization details, entry criteria, and secondary endpoints.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
27
The slide features the MindMed logo and the specific drug candidate and trial phase.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
28
The slide emphasizes regulatory alignment and standard clinical trial methodology.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
29
Includes study arms, dosing, follow-up timeline, entry criteria, and secondary endpoints.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
30
Uses a comparison table to define what is and is not part of the patient journey.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
31
The slide uses a CONSORT-style flow diagram to track patient retention.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
32
The table displays mean age, sex distribution, race, and baseline HAM-A and CGI-S scores for n=194 participants.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
33
The chart highlights the efficacy of the 100ug dose group specifically in the callout box.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
34
Data compares Placebo, 25ug, 50ug, 100ug, and 200ug doses.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
35
MCP-Mod is a statistical methodology for dose-response modeling.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
36
The chart shows a clear separation between placebo and treatment groups across time points.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
37
The slide uses a structured list format to present safety outcomes.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
38
The table highlights that while adverse events occur, they are largely concentrated on the dosing day, suggesting a favorable tolerability profile.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
39
MindMed | Investor Presentation Deck | 42 slidesMindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
40
The slide uses a combination of a cellular-level mechanism diagram and a brain-region-level diagram to explain the drug's effect.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
41
The slide uses a bar chart to demonstrate efficacy in an animal model and an icon grid to summarize clinical benefits.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
42
This slide serves as a divider or cover page within the deck.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit